依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的疗效与安全性观察

Efficacy and safety of edaravone dexcamphenol in the treatment of acute cerebral infarction

目的观察依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的疗效及安全性。方法将急性脑梗死患者随机分成观察组(依达拉奉右莰醇注射用浓溶液+常规治疗)和对照组(常规治疗),予以治疗14 d。两组患者入院时和治疗14 d时分别予以美国国立卫生研究院卒中量表(NIHSS)评估患者神经功能,和改良的Rankin量表(mRS)评估患者日常生活能力,同期检测C反应蛋白(CRP),并观察患者治疗期间有无药物不良反应发生。结果实验组患者治疗前后NIHSS评分、mRS评分及CRP水平差值较对照组均显著降低,差异具有统计学意义(均P<0.05);两组患者治疗期间均未发生药物不良反应。结论依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的疗效显著,安全性较高。

Objective To investigate the efficacy and safety of edaravone dexcamphenol in the treatment of acute cerebral infarction.Methods Patients with acute cerebral infarction were randomly divided into observation group(edaravone dexborneol+conventional treatment)and control group(conventional treatment)for 14 days.Neurological function was assessed by the National Institutes of Health Stroke Scale(NIHSS)at admission and the modified Rankin Scale(mRS)at 14 days after treatment,respectively.C-reactive protein(CRP)level was detected simultaneously.Furthermore,the occurrence of adverse drug reactions during treatment was observed.Results NIHSS score,mRS score and CRP levels in experimental group were significantly lower than those in control group(all P<0.05).No adverse drug reactions in the two groups were observed during treatment.Conclusion Edaravone dexborneol has a significant clinical effect in the treatment of acute cerebral infarction,and the safety of this treatment is relatively high.